Investigation, Z.Z., Q.X., X.C., L.W., J.W
Step 2: Choose Your Format We offer our Liposomal Glutathione in a convenient liquid pouch

Disclosures: Jun Tsuchiya: Nothing to Disclose, Masato Miyoshi: Nothing to Disclose, Sei Kakinuma: Nothing to Disclose, Taro Shimizu: Nothing to Disclose, Keiya Watakabe: Nothing to Disclose, Tomohiro Mochida: Nothing to Disclose, Kento Inada: Nothing to Disclose, Shun Kaneko: Nothing to Disclose, Fukiko Kawai-Kitahata: Nothing to Disclose, Sayuri Nitta: Nothing to Disclose, Miyako Murakawa: Nothing to Disclose, Mina Nakagawa: Nothing to Disclose, Yasuhiro Asahina: Nothing to Disclose, Ryuichi Okamoto: Nothing to Disclose 1807 METTL3-MEDIATED M6A MODIFICATION REGULATES THE POLYCOMB REPRESSIVE COMPLEX 1 (PRC1) COMPONENTS BMI1 AND RNF2 IN HEPATOCELLULAR CARCINOMA CELLS Weina Chen Jinqiang Zhang 1 Wenbo Ma 1 Nianli Liu 1 Tong Wu 1 , 1 Tulane University Background: Methyltransferase- like 3 (METTL3) is a primary RNA methyltransferase that catalyzes N6-methyladenosine (m6A) modification which is implicated in several human cancers including hepatocellular carcinoma (HCC), although its mechanism of action remains to be further defined

As NAD+ levels drop with age, our cells become more vulnerable to damage
Due to the lack of clinical studies on some drugs, the efficacy of ferroptosis inhibitors in a clinical setting remains undetermined
Proc Natl Acad Sci U S A 115(37):E8717e8726 Acknowledgements The figures of this paper were created by Biorender.com